ABIONYX Pharma S.A.
ABNX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -7.60 | -2.24 | -0.08 | 0.16 |
| FCF Yield | -4.02% | -4.13% | -5.03% | -2.97% |
| EV / EBITDA | -18.90 | 19.89 | -15.52 | -34.74 |
| Quality | ||||
| ROIC | -23.43% | -15.48% | -16.53% | -10.21% |
| Gross Margin | 10.85% | 26.46% | 12.93% | 25.04% |
| Cash Conversion Ratio | 0.74 | 0.75 | 0.90 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 599.27% | 2,098,311.50% | 280.77% | 284.51% |
| Free Cash Flow Growth | 0.18% | 10.23% | -58.74% | 54.21% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | -0.23 | 0.93 | 0.63 |
| Interest Coverage | -40.17 | -123.21 | -61.60 | -8.58 |
| Efficiency | ||||
| Inventory Turnover | 9.09 | 7.86 | 10.15 | 8.52 |
| Cash Conversion Cycle | 21.33 | 14.63 | 29.99 | -25.29 |